Última Hora
Volver al inicio
Noticias2 min de lectura

Redacción de Today's Trending

Actualidad sobre Semaglutide

Semaglutide genera amplia cobertura tras los reportajes de The Times of India y otros medios.

Foto: Ophthalmology Advisor. Imagen mostrada a través del editor original o índice de noticias. Todos los derechos pertenecen al titular correspondiente.

Compartir𝕏fWTin
Actualidad sobre Semaglutide

Semaglutide se ha convertido en una noticia de gran relevancia, con los primeros reportajes de The Times of India marcando el rumbo de la cobertura.

Cobertura relacionada

El interés en Semaglutide refleja la rapidez con la que una historia puede captar la atención global. Al menos 2 medios han publicado información adicional.

Lo que informan los medios

Today's Trending seguirá actualizando esta cobertura a medida que surjan nuevos reportajes.

Extractos atribuidos

“Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that…”

“Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating…”


Cobertura relacionada

1. ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian…

Medio: The Times of India

Leer la noticia completa →

2. A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG)…

Medio: The South First

Leer la noticia completa →

De nuestra red

ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that Endoscopic Sleeve Gastroplasty (ESG), a non-surgical procedure, helped patients lose weight faster than oral semaglutide tablets in the short term. After a year, though, the difference narrowed.The AIG Hospitals study has been published in the peer-reviewed journal Endoscopy.As part of the study, researchers Dr D Nageshwar Reddy, Dr Nitin Jagtap, and Dr Rakesh Kalpala, compared 150 adults with obesity treated between January 2024 and April 2025. Around 50 patients underwent ESG, while 100 received oral semaglutide 14 mg along with standard lifestyle modification. At six months, patients who underwent ESG achieved an average total body weight loss of 12.72%, compared with 8.67% among those taking oral semaglutide. Around 70% of ESG patients lost at leas…

The Times of India

A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating obesity. Researchers found ESG produced greater weight loss at six months, while oral semaglutide largely caught up after one year. The findings highlight how treatment choice depends on patient goals, convenience and long-term care. An obese patient in Hyderabad asked a doctor a question that has become very common in recent times, "Should I undergo a procedure, or should I take a tablet?" Earlier, diet sheets and gym routines used to dominate conversations about obesity. Surgery waited at the far end, reserved for patients who had tried everything else. Now, that map has shifted. Patients weigh the stomach procedure against a hormone tablet. No one had tested the two against each other in the same group until doctors at AIG Hospitals in Hyderabad ran that…

The South First